About Us


We understand that many of the lives of those who need our products have been touched by tragedy and are changed forever.

At PolyNovo, we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible.

PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology NovoSorb®.

NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways.

NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with NovoSorb BTM for full thickness burns.

We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.

NovoSorb BTM milestones


CSIRO and PolyNovo collaboration with Prof. John Greenwood results in development of NovoSorb BTM


Pre-clinical studies and factory established in Port Melbourne


First patient treated with NovoSorb BTM


United States 510(K) clearance and commercialization


Australian TGA registration


European CE Mark and US FDA Breakthrough Device Designation


First patient enrolled in the Biomedical Advanced Research and Development Authority (BARDA) and US FDA pivotal trial


Market access in 37 countries